Hyperkalemia
Potassium monitoring device saves money, increases quality of life in patients on dialysis
ORLANDO — Using a real-time potassium monitoring device in patients on hemodialysis saves more money than the usual care and increases quality of life, according to a presenter at ASN Kidney Week.
Dietary potassium intake linked with blood potassium concentration in patients with CKD
Among patients with advanced chronic kidney disease, increasing dietary potassium consumption to recommended levels can increase blood potassium concentration on a short-term basis, according to results of this study.
No association between interactive voice response system, improved kidney outcomes
Patients with stage 3 to 5 chronic kidney disease who used an interactive voice response system did not experience significant changes in kidney outcomes compared with patients who received usual care.
Video: DIAMOND study probes patiromer’s use in reducing hyperkalemia
In this video, Uri Elkayam, MD, gave Healio an in-depth look at the DIAMOND study presented at the American College of Cardiology Scientific Session.
DIAMOND
Patiromer for prevention of hyperkalemia and maintenance of renin-angiotensin-aldosterone inhibitor use in patients with HF with reduced ejection fraction.
VIDEO: NKF chief medical officer reviews late-breaking trials
BOSTON — In this video from the National Kidney Foundation Spring Clinical Meetings, Joseph A. Vassalotti, MD, reviews results from late-breaking clinical trials.
Video: DIAMOND study provides ‘interesting data’ on hyperkalemia reduction
In this video, David E. Lanfear, MD, advanced HF specialist and program director of the Advanced Heart Failure Fellowship at the Henry Ford Health System in Detroit, spoke to Healio about two clinical trials presented at the American College of Cardiology Scientific Session.
VIDEO: Butler reviews benefits of patiromer observed in DIAMOND trial
WASHINGTON — In this Healio video exclusive, Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC, discusses the results of the DIAMOND trial of patiromer for the reduction of hyperkalemia in patients with HF with reduced ejection fraction.
Study shows patiromer reduces potassium levels, lowers risk of heart failure drugs in CKD
Patiromer enables optimal medical therapy, prevention of hyperkalemia in HFrEF
WASHINGTON — Patiromer, a novel potassium binder, was associated with a reduction in hyperkalemia in patients with HF with reduced ejection fraction, enabling an increase in adherence to optimal medical therapy, researchers reported.